Cases & Deals

Celgene invests in PTC Therapeutics

Clients Celgene Corporation

Jones Day advised Celgene Corporation in connection with its purchase of $20 million of Convertible Preferred Stock in a private placement by PTC Therapeutics, Inc., a biopharmaceutical company.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.